ZLD.AX Zelira ASX jumps 136.11% to A$0.85 16 Jan 2026: high-volume catalyst
ZLD.AX stock surged 136.11% to A$0.85 at market close on 16 Jan 2026, driven by a dramatic volume spike of 800,818 shares. The move put the day high at A$1.01 and closed well above the 50-day average of A$0.37 on the ASX in Australia. Traders flagged the outsized liquidity relative to an average daily volume of 3,683 shares. We review the drivers, valuation, technicals and what Meyka AI’s models project next for Zelira Therapeutics (ZLD.AX stock).
ZLD.AX stock: the high-volume move and market context
ZLD.AX stock jumped 136.11% to A$0.85 with 800,818 shares traded, far above the 3,683 average volume. The day range was A$0.415–A$1.01, and the prior close was A$0.36. This volume-led move classifies Zelira Therapeutics as a high-volume mover on the ASX. The company is listed on the ASX in Australia and has 11,897,155 shares outstanding and a market cap of A$4,282,976.
Trading drivers and ZLD.AX stock news flow
There was no confirmed ASX market announcement tied to the spike at close. Zelira’s product portfolio and US HOPE brand presence can attract episodic interest, but today’s trade appears driven by speculative flows and retail momentum. Investors should check company filings and the corporate site for updates: Zelira Therapeutics website. Social channels such as the company Twitter may show the chatter behind volume: Zelira Twitter.
Financial snapshot and valuation for Zelira Therapeutics (ZLD.AX stock analysis)
Zelira reports EPS of -0.32 and a trailing PE of -1.12, reflecting persistent losses. Key metrics show weak liquidity: current ratio 0.11 and cash per share A$0.00. Price-to-sales is elevated at 6,538.89, and enterprise value is A$6,418,753. Revenue per share is negligible at 0.000056 and operating cash flow per share is -0.42. These figures underline a biotech at an early commercial stage with high valuation multiples versus limited revenue.
Technical view and Meyka AI rates ZLD.AX with a score out of 100
Technicals show a short-term strength: RSI 58.09, ADX 34.87 indicating a strong trend, and MACD histogram near zero. Bollinger middle band is A$0.38. Volume indicators confirm the spike is unusual versus average volume. Meyka AI rates ZLD.AX with a score out of 100: 64.99 (Grade B, HOLD). This grade factors S&P 500 and sector comparisons, financial growth, key metrics and analyst signals. These grades are not guarantees and we are not financial advisers.
Risks, outlook and ZLD.AX stock forecast
Major risks include low cash reserves, negative margins, and high operating cash burn. Zelira’s next reported earnings date is 24 Feb 2026, which could reprice the stock. Meyka AI’s forecast model projects a monthly target of A$0.22, implying an implied downside of -74.12% versus the current A$0.85. Forecasts are model-based projections and not guarantees. Traders should weigh the company’s biotech sector volatility and low liquidity when sizing positions.
Price targets, trader signals and what to watch next for ZLD.AX stock
We set a conservative short-term price target of A$0.50 and a bullish scenario target of A$1.20 based on technical momentum and potential news catalysts. That implies downside to A$0.50 of -41.18% and upside to A$1.20 of +41.18% from today’s price. Watch the ASX announcements, the Feb 24 earnings date, volume sustainment, and any commercial updates on HOPE or Zenivol product channels. Use tight risk controls given the company’s financials.
Final Thoughts
ZLD.AX stock led ASX high-volume movers on 16 Jan 2026, rising 136.11% to A$0.85 on 800,818 shares. The spike outpaced the 50-day average and pushed price above short-term technical bands, but fundamentals remain challenged with EPS -0.32, a weak current ratio 0.11, and heavy negative cash flow. Meyka AI’s forecast model projects a monthly level of A$0.22, implying -74.12% versus today’s price; this highlights the gap between speculative momentum and model valuations. For traders, the key decision is whether volume and follow-through validate a breakout, or whether the move is a short squeeze ahead of the earnings report on 24 Feb 2026. We recommend clear stop-loss levels and small position sizing given Zelira Therapeutics’ (ZLD.AX) liquidity profile and biotech sector volatility. Meyka AI provides this AI-powered market analysis as data-driven context, not financial advice.
FAQs
Why did ZLD.AX stock jump today?
ZLD.AX stock jumped on 16 Jan 2026 due to heavy trading volume of 800,818 shares. There was no confirmed ASX announcement at close; the move looks driven by speculative flows and retail interest. Check company filings for any later disclosures.
What are the key financial risks for ZLD.AX stock?
Key risks include negative EPS -0.32, low current ratio 0.11, negative operating cash flow per share -0.42, and high price-to-sales 6,538.89. These point to funding and execution risk for Zelira Therapeutics on the ASX.
What price targets and forecast exist for ZLD.AX stock?
Meyka AI’s forecast model projects a monthly figure of A$0.22, implying -74.12% from A$0.85. We note a conservative target A$0.50 and an upside target A$1.20. Forecasts are model-based and not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
